JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM

NCT04208464 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Manchester

Collaborators